Results 61 to 70 of about 31,567 (277)
Movement Disorders in Aicardi–Goutières Syndrome and Response to Immunomodulation
ABSTRACT This study characterizes movement disorders and treatment responses in seven children with Aicardi–Goutières syndrome (AGS). We retrospectively evaluated motor phenotypes, neuroimaging, and interferon signatures in patients treated with baricitinib or anifrolumab. Spasticity affected all patients, while dystonia was present in 4/7.
Enrique Gonzalez Saez‐Diez +10 more
wiley +1 more source
Selective reversible JAK1 inhibitor in the treatment of moderate and severe atopic dermatitis
In recent decades, industrialized countries have recorded a steady increase in the incidence of atopic dermatitis (AD). The pathogenesis of AD is complex and diverse and includes hereditary determinism leading to a disruption of the skin barrier, as well
Yu. S. Kovaleva +2 more
doaj +1 more source
A long‐lived, five‐cell‐type human neurovascular (PENTA) model recreates vascular disorganization and incomplete repair after traumatic brain injury (TBI). By integrating endothelial, glial, neuronal, and immune components within a 3D scaffold, the platform enables time‐resolved analysis of neurovascular remodeling and provides a human‐relevant system ...
Daniel S. Hinrichsen +6 more
wiley +1 more source
Novel protein kinase signaling systems regulating lifespan identified by small molecule library screening using Drosophila. [PDF]
Protein kinase signaling cascades control most aspects of cellular function. The ATP binding domains of signaling protein kinases are the targets of most available inhibitors. These domains are highly conserved from mammals to flies.
Stephen R Spindler +4 more
doaj +1 more source
Role of JAK-STAT signaling pathway in pathogenesis and treatment of primary Sjögren's syndrome
. Primary Sjögren's syndrome (pSS) is a systemic autoimmune disease with high prevalence and possible poor prognosis. Though the pathogenesis of pSS has not been fully elucidated, B cell hyperactivity is considered as one of the fundamental abnormalities
Mucong Li +7 more
doaj +1 more source
Targeting Lilrb4a in Apolipoprotein E4 (APOE4)‐associated Alzheimer's disease (AD) reprograms microglia toward a beneficial, phagocytic state. Genetic deletion or antisense inhibition of Lilrb4a suppresses p‐SHP2/NF‐κB/STAT1 signaling, restores PPAR‐linked lipid and energy metabolism, and reduces amyloid plaque burden and cerebral amyloid angiopathy ...
Changxu Nie +12 more
wiley +1 more source
A Comprehensive Overview of Globally Approved JAK Inhibitors
Janus kinase (JAK) is a family of cytoplasmic non-receptor tyrosine kinases that includes four members, namely JAK1, JAK2, JAK3, and TYK2. The JAKs transduce cytokine signaling through the JAK-STAT pathway, which regulates the transcription of several ...
Ahmed M. Shawky +4 more
doaj +1 more source
Triple‐negative breast cancer (TNBC) cells evade natural killer (NK) cell immunity by secreting IL8 and CXCL1. These chemokines suppress NK cells’ function via CXCR1/2 and enhance cancer cells’ survival through PD‐L1 upregulation and BCL‐2 anti‐apoptotic signaling.
Mingheng Yuan +6 more
wiley +1 more source
Mechanisms of SOCS3 phosphorylation upon interleukin-6 stimulation. Contributions of Src- and receptor-tyrosine kinases. [PDF]
peer reviewedThe suppressors of cytokine signaling (SOCS) are negative feedback inhibitors of cytokine signal transduction. SOCS3 is a key negative regulator of interleuking-6 (IL-6) signal transduction.
Sobota, Radoslaw M. +20 more
core +3 more sources
The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease [PDF]
Inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease, are disabling conditions characterised by chronic, relapsing inflammation of the gastrointestinal tract.
de Jonge, Wouter +3 more
core +1 more source

